Hypothesis

Rapamycin and caloric restriction extend lifespan not by constantly suppressing mTOR or HBP flux, but by generating metabolic oscillations that periodically lower HBP flux, allowing windows of autophagy activation and proteostatic remodeling. Sustained HBP suppression would be detrimental; the benefit arises from the cyclic nature of the signal.

Mechanistic Rationale

1. mTORC1 drives glutamine uptake via SLC1A5, providing a key substrate for the hexosamine biosynthetic pathway (HBP). Inhibition of mTORC1 rapidly reduces intracellular glutamine, lowering GFAT1 activity and thus HBP flux.
2. HBP flux inversely regulates autophagy: during glucose deprivation, GFAT1 enhances autophagy, and O‑GlcNAc cycling modulates proteasome activity. When HBP flux drops, autophagy is up‑regulated; when flux rebounds, O‑GlcNAcylation transiently shields aggregation‑prone proteins (e.g., tau) from damage.
3. Oscillatory nutrient sensing creates a biphasic O‑GlcNAc landscape: low‑flux phases trigger clearance of damaged proteins via autophagy; high‑flux phases provide protective O‑GlcNAc modifications that prevent irreversible aggregation. This mirrors the protective‑then‑clearance cycle seen in acute stress responses.
4. Constant HBP suppression (e.g., chronic glucosamine depletion) would impair the protective O‑GlcNAc shielding phase, leading to increased susceptibility to proteotoxic stress despite high autophagy. Conversely, constant HBP activation (as with sustained glucosamine supplementation) blocks autophagy, causing accumulation of damaged components.

Testable Predictions

• Prediction 1: In mice, rapamycin will extend lifespan only when glutamine availability oscillates (e.g., alternating high‑glutamine/low‑glutamine weeks). Constant high‑glutamine diet will abolish rapamycin’s survival benefit despite equivalent mTORC1 inhibition.
• Prediction 2: Oscillating glutamine will produce rhythmic changes in hepatic O‑GlcNAc levels (peak during high‑glutamine phases, trough during low‑glutamine phases) that correlate with periodic spikes in LC3‑II/I ratio and p62 degradation.
• Prediction 3: Genetic attenuation of GFAT1 (liver‑specific heterozygous knockout) will blunt the lifespan extension of rapamycin under oscillating glutamine, because the low‑flux autophagy boost is lost.
• Prediction 4: Pharmacological GFAT1 activation during the low‑glutamine phase will suppress autophagy and reduce longevity, confirming that the timing of HBP suppression matters.

Experimental Design

1. Animal cohorts (C57BL/6, n=30 per group):
   • Control diet (standard protein, glutamine).
   • Rapamycin + standard diet.
   • Rapamycin + intermittent glutamine diet (1 week high glutamine (2% w/w), 1 week low glutamine (0.2% w/w) cycled).
   • Rapamycin + constant high glutamine diet.
   • Rapamycin + constant low glutamine diet.
   • Each diet arm with or without liver‑specific GFAT1 heterozygous knockout.
2. Measurements (every 3 months):
   • Plasma glutamine, O‑GlcNAc levels (Western blot of liver lysates).
   • Autophagic flux (LC3‑II/I, p62, tandem mCherry‑GFP‑LC3).
   • Proteasome activity assay.
   • Frailty index and survival.
3. Endpoints: median and maximal lifespan, cause‑of‑death histopathology.

Falsifiability

If rapamycin extends lifespan equally across all glutamine regimens (constant high, constant low, oscillating) and lifespan extension correlates solely with the degree of mTORC1 inhibition (e.g., p‑S6K levels), then the hypothesis that metabolic oscillations in HBP flux are essential is falsified. Conversely, if only the oscillating glutamine group shows significant lifespan extension coupled with the predicted O‑GlcNAc/autophagy rhythms, the hypothesis is supported.

Broader Implication

This reframes longevity interventions as dynamic nutrient‑sensing programs rather than static pathway inhibition, suggesting that timing‑based dietary or pharmacological regimens could optimize healthspan by exploiting the cell’s innate stress‑response cycles.